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Abstract
Good practice in clinical trials advocates common standards for assessing and reporting condition-specific complaints (‘‘out-
come domains’’). For tinnitus, there is no common standard. The Core Outcome Measures in Tinnitus International Delphi
(COMiT’ID) study created recommendations that are relevant to the most common intervention approaches for chronic
subjective tinnitus in adults using consensus methods. Here, the objectives were to examine why it is important to tailor
outcome domain selection to the tinnitus intervention that is being evaluated in the clinical trial and to demonstrate that the
COMiT’ID recommendations are robust. The COMiT’ID study used an online three-round Delphi method with three
separate surveys for sound-, psychology-, and pharmacology-based interventions. Survey data were analyzed to assess quality
and confidence in the consensus achieved across surveys and stakeholder groups and between survey rounds. Results found
participants were highly discriminatory in their decision-making. Of the 34 outcome domains reaching the prespecified
consensus definition in the final round, 17 (50%) were unique to one intervention, while only 12 (35%) were common to
all three. Robustness was demonstrated by an acceptable level of agreement across and within stakeholder groups, across
survey rounds, across medical specialties (for the health-care practitioners), and across health-care users with varying
tinnitus duration. There were few dissenting voices, and results showed no attrition bias. In conclusion, there is compelling
evidence that one set of outcomes does not fit all therapeutic aims. Our analyses evidence robust decisions by the electronic
Delphi process, leading to recommendations for three unique intervention-specific outcome domain sets. This provides an
important starting point for standardization.
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Introduction
Subjective tinnitus describes the conscious perception of
an auditory sensation that can be experienced only by
the individual and is in the absence of a corresponding
external stimulus. Subjective tinnitus is a common, yet
very heterogeneous condition whose perceptual charac-
teristics and impacts can vary greatly from person to
person (Hall et al., 2018). Tinnitus has no singularly
eﬀective treatment, and hence, a number of clinical spe-
cialities have responsibility for provision of patient care
including, but not restricted to, general practitioners,
otologists, audiologists, clinical psychologists, neurolo-
gists, physical therapists, and psychiatrists. Through
these health-care professionals, patients are able to
access a wide range of therapeutic interventions includ-
ing drug medications, sound therapies, talking-based
therapies, relaxation techniques, neuromodulation, phys-
ical therapy, and complementary and alternative thera-
pies (Baguley, McFerran, & Hall, 2013). The most
common intervention approaches evaluated in clinical
trials to date are the ﬁrst three listed involving medica-
tions, sound therapy, and psychology-based strategies
(Hall et al., 2016).
Randomized trials, and systematic reviews of such
trials, provide the most reliable evidence about the eﬀects
of existing health-care interventions in terms of how they
compare against one another and how new interventions
compare with existing ones (Higgins et al., 2011). Well-
conducted clinical trials can make a signiﬁcant impact on
patient care by inﬂuencing regulatory body decisions,
development of clinical guidelines, and commissioning
of health-care provision (Higgins et al., 2011; Tunkel
et al., 2014; U.S. Department of Health and Human
Services Food and Drug Administration, 1998). For
these organizations, conﬁrmatory evidence helps to
establish a deﬁnitive answer to the question of clinical
eﬃcacy. Conﬁrmatory evidence requires a predeﬁned
hypothesis about the expected treatment beneﬁt and a
trial design that provides highly reliable and statistically
strong evidence of an important clinical beneﬁt (Higgins
et al., 2011; U.S. Department of Health and Human
Services Food and Drug Administration, 1998). For
example, in the case of tinnitus, the hypothesis should
consider what tinnitus-related complaints are to be alle-
viated by the intervention of interest and how they
should be measured quantitatively so that the sample
size can be adequately powered and a statistical analysis
can be conducted.
To this end, our study focused on outcomes for assess-
ing the eﬃcacy of three families of interventions (sound,
psychology, and pharmacology). We chose these not
only because they are in common practice but also
because each has a diﬀerent therapeutic rationale, and
so clinical outcomes might reasonably diﬀer across inter-
ventions according to how the interventions is supposed
to be working and their likelihood of showing a treat-
ment-related change. The study focused on outcome
domains that refer to any aspect of tinnitus that is
or can be experienced by a patient. Examples include
tinnitus loudness, tinnitus annoyance, the ability to con-
centrate, sense of control, or impact on work. The aim of
the study was to identify a minimum set of outcome
domains that are considered important for each of
the three families of interventions, and this should
inform the choice of measurement instruments used in
clinical trials.
For tinnitus, the outcome domains and measurement
instruments reported in clinical trials are numerous and
diverse (Hall et al., 2016), and this precludes compari-
sons across interventions, as well as pooling the evidence
for one type of intervention across studies (e.g.,
Martinez-Devesa, Perera, Theodoulou, & Waddell,
2010). One of the biggest barriers to good clinical trial
design in tinnitus is the insuﬃcient evidence base for
choosing which outcomes should be assessed in clinical
trials (e.g., Landgrebe et al., 2012; Londero & Hall, 2017;
Tyler, Oleson, Noble, Coelho, & Ji, 2007). The current
diversity and lack of agreed standards impedes the ability
to conﬁdently select the most valid and best performing
measurement instrument for quantifying expected treat-
ment-related change for a tinnitus intervention (see
Prinsen et al., 2018; Terwee et al., 2018).
The most popular measurement instruments are those
that assess tinnitus as a composite multidomain con-
struct, and these are used somewhat interchangeably to
test a wide range of tinnitus interventions (Hall et al.,
2016). The Tinnitus Handicap Inventory (Newman,
Jacobsen, & Spitzer, 1996), Tinnitus Questionnaire
(TQ; Hallam, 2009), and Tinnitus Handicap
Questionnaire (THQ; Kuk, Tyler, Russell, & Jordan,
1990) are just three examples. However, the tinnitus
domains captured by each can dramatically diﬀer
across instruments, and few conventions apply. To illus-
trate this point, we brieﬂy compare two multidomain
instruments in common usage. On one hand, the TQ
has 52 items covering distress, intrusiveness, hearing
diﬃculties, sleep disturbance, and somatic complaints
(Hallam, 2009), while on the other, the THQ has 27
items covering social, emotional, and behavioral eﬀects;
hearing diﬃculties; and outlook on tinnitus (Kuk et al.,
1990). Both the domains and content of the items diﬀer
substantially from one to the other (Kennedy, Wilson, &
Stephens, 2004). For example, the TQ asks about pain in
the ear or head and tension in the head or neck muscles,
while the THQ does not address these somatic com-
plaints at all. Moreover, despite some common domains
across the TQ and THQ, the weighting of items diﬀers
substantially from one to the other (Kennedy et al.,
2004). For example, the TQ has proportionately more
items asking about emotional distress than does the
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THQ (37% vs. 22%), while the THQ has proportion-
ately more items asking about hearing than does the
TQ (19% vs. 13%).
The Tinnitus Guideline Development Group acting
on behalf of the American Academy of Otolaryngology
Head and Neck Surgery has appealed for further
research to ‘‘determine which questionnaire is most
useful for assessing relevant treatment eﬀects’’ (Tunkel
et al., 2014, p. S32). A ﬁrst step toward creating the evi-
dence base to determine such answers is to identify which
outcome domains are most relevant for covering the
wide range of therapeutic interventions that are available
for tinnitus. At least then, tinnitus investigators would
know if any of the common measurement instruments
cover all of the tinnitus-related complaints that are con-
sidered to be critically important for clinical trials of
their intervention of interest.
This article forms a companion to Hall et al. (2018),
also in this Special Collection, reporting the Core
Outcome Measures in Tinnitus International Delphi
(COMiT’ID) study. The COMiT’ID study has made spe-
ciﬁc sets of recommendations about core outcome
domains that diﬀer according to whether a clinical trial
is testing sound-, psychology-, or pharmacology-based
interventions for tinnitus. Because these recommendations
are new and challenge current practice, this article
examines the basis for the recommendations, reporting
a series of in-depth analyses of the COMiT’ID study
data. The main objectives in this article are to explain
why it is important to tailor outcome domain selection
to the tinnitus intervention that is being evaluated in
the clinical trial and to demonstrate that the outcome
domain recommendations achieved by the COMiT’ID
study electronic Delphi (e-Delphi) consensus method
are robust.
Methods
Study design followed best practice recommendations set
out in the Core Outcome Measures for Eﬀectiveness in
Trials (COMET) handbook v1.0 (Williamson et al.,
2017). The COMiT’ID study considered sound-, psych-
ology-, and pharmacology-based interventions for tin-
nitus because these three approaches are in most
frequent usage across clinical practice internationally
(Hall et al., 2011, 2016). The study comprised three
phases: (a) three e-Delphi surveys to prioritize outcome
domains for each family of interventions, (b) three struc-
tured face-to-face meetings to reduce the set of outcome
domains to a number feasible for a clinical trial, and (c)
an electronic vote on the ﬁnal recommendations. Phases
2 and 3 followed the COMET handbook recommenda-
tion that ‘‘representatives of key stakeholder groups have
the opportunity for discussion of the results of the sur-
veys to agree a ﬁnal core set and undertake additional
voting if required before a ﬁnal COS is agreed’’
(Williamson et al., 2017, p. 24). This article focuses
only on the ﬁrst phase because this was a substantive
part of the COMiT’ID study, created the ﬁrst wave of
recommendations, and had the broadest input from the
international tinnitus community. Further information
on the methods in Phase 1 can be found in the published
protocol (Fackrell et al., 2017) and in the companion
article (Hall et al., 2018), but here, we provide a sum-
mary of the key design features.
Participants
The study team took a number of steps to safeguard the
relevant expertise of participants. First, recruitment was
targeted in a purposeful manner through invitation.
For professionals, the study team created a contacts
list of 592 named individuals who were personally nomi-
nated by the members of TINnitus NETwork outcome
measurement working group, identiﬁed as authors
of relevant tinnitus conference proceedings in the past
3 years, authors of the clinical trials of tinnitus included
in our previous systematic review (Hall et al., 2016),
authors of systematic reviews of tinnitus interventions
published in the past 5 years (Cochrane or otherwise),
or editors of scholarly journals in Audiology or Otology.
Health-care users were targeted using planned recruit-
ment routes that included designated clinical centers,
as well as a number of national and international
professional networks and organizations.
Second, as part of the study enrolment process at the
point of obtaining informed consent, all participants
were required to sign a self-declaration statement
conﬁrming that they met one of the following eligibility
criteria:
1. Health-care users were required to have experienced
tinnitus for a minimum of 3 months and have current
or past experience with, or be considering trying in
the future, a sound-, psychology-, or pharmacology-
based tinnitus intervention.
2. Health-care professionals were required to be
clinically qualiﬁed and actively working within a
health-care institution providing a service to adults
with tinnitus, speciﬁcally those who receive a sound-,
psychology-, or pharmacology-based intervention.
3. Clinical researchers were required to be academically
qualiﬁed and actively working within a research
organization, either currently conducting or having
recently conducted research regarding clinical eﬃcacy
of a sound-, psychology-, or pharmacology-based
intervention for tinnitus.
4. Commercial representatives were required to work
for a company that develops, manufactures, or sells
sound- or pharmacology-based products for tinnitus.
Hall et al. 3
5. Funders were required to work for an organization
that had recently funded relevant tinnitus research.
Commercial representatives and funders were pooled
in the same stakeholder group, as per protocol (Fackrell
et al., 2017), because anticipated numbers for each were
smaller than for other groups. There was no planned
group for commercial representatives and funders in
the survey on psychology-based interventions. Table 1
displays the number of participants in each of the
four stakeholder groups at each round of the three
e-Delphi surveys. All participants gave informed con-
sent, and the study was approved by the Solihull
Research Ethics Committee and Health Research
Authority (ref: 17/WM/0095, March 2017).
e-Delphi Surveys
The starting point for the e-Delphi was a long list of 66
candidate outcome domains. This was created via three
sources: (a) systematic review of outcome domains used
in clinical trials of tinnitus treatment in adults (Hall
et al., 2016), (b) narrative synthesis of tinnitus-related
complaints reported by patients (Hall et al., 2018), and
(c) content analysis of outcome domains assessed by
items in commonly reported tinnitus questionnaires.
The process identiﬁed 123 unique outcome domains
that were then reﬁned to 66 through a series of health-
care user-led decisions considering which were speciﬁc to
tinnitus, distinct in construct, and not associated with
how to measure the construct (Fackrell et al., 2017;
Smith et al., 2018). For each outcome domain, a plain
language concept deﬁnition was coproduced with health-
care users so that all participants could understand its
meaning. The labeling given to each outcome domain
was also conducted with patient input. The ﬁnal version
is published as Additional File 1 (Fackrell et al., 2017).
There were three independent e-Delphi surveys; one for
sound-, psychology-, and pharmacology-based interven-
tions, respectively. The same list of 66 outcome domains
was presented in a ﬁxed order in all three surveys, accord-
ing to the following categories: behavior, body structures
and functions, cognition (thought processes), coping and
acceptance, eﬀects of tinnitus on hearing, emotions, factors
related to the treatment being tested, health-related quality
of life, negative thoughts, perceptions of the tinnitus
sound, physical health, state of mind, and support and
knowledge. Participants were asked to think about each
tinnitus outcome domain with respect to how important it
would be to measure when deciding if a sound-, psych-
ology-, or pharmacology-based tinnitus treatment is work-
ing. They were asked to consider its relevance and
likelihood to show a treatment-related change for all inter-
ventions within that family. Participants scored each indi-
vidual outcome domain using a 1 to 9 scale, whereby 1 to 3
indicated that the domain was not important, 4 to
Table 1. Number of Participants in Each Stakeholder Group and for Each Intervention Type That Consented and
Participated in Each Round of the e-Delphi Survey.
Stakeholder group Consented
e-Delphi
Round 1
e-Delphi
Round 2
e-Delphi
Round 3 Attrition (%)
Sound-based interventions
Health-care user 199 182 160 142 22.0
Health-care practitioner 79 70 60 57 18.6
Clinical researchers 36 35 35 34 2.9
Commercial reps and funders 24 21 19 19 9.5
Psychology-based interventions
Health-care user 118 114 97 89 21.9
Health-care practitioner 63 61 57 50 18.0
Clinical researchers 39 39 37 36 7.7
Commercial reps and funders 4 4 4 3 N/A
Pharmacology-based interventions
Health-care user 67 62 48 41 33.9
Health-care practitioner 51 47 40 37 21.3
Clinical researchers 20 17 14 13 23.5
Commercial reps and funders 19 18 15 12 33.3
Total 719a 670 586 533b 20.4
Note. Attrition refers to the percent who withdrew or dropped out between Rounds 1 and 3.
aNote some individuals consented to participate in more than one study, and so when those duplicates have been accounted for, the
719 comprises 641 unique individuals.
bFor those participating in more than one study, when duplicates have been accounted for, the 533 comprises 472 unique individuals.
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6 indicated it was important but not critical, and 7
to 9 indicated that it was critically important in deciding
whether a tinnitus intervention is eﬀective (Guyatt et al.,
2011). Following the COMET handbook v1.0, the study
design also included an unable to score category to allow
for the fact that some participants may not have the level
of expertise to score certain outcomes. Over the three e-
Delphi surveys, 1% to 2% of all responses were of this
type. As expected, most often it was health-care users who
chose to use this option, and least often it was clinical
researchers. In Round 1, there were also open-text boxes
for adding comments beside each outcome domain.
In Round 1, participants could nominate additional
outcome domains that they felt had been missed from
the initial list of 66, and 8 new outcome domains were
added in total (2 for sound, 4 for psychology, and 2 for
pharmacology). Frequency of occurrence of tinnitus epi-
sodes’ was added to both sound and pharmacology, hence
one outcome was repeated. In Rounds 2 and 3, partici-
pants received (numerical and graphical) feedback on the
distribution of scores for the 66 outcome domains, and
the new outcome domains were presented for scoring.
Round 2 enabled participants to reﬂect on their scores
in light of the distribution of scores for their own stake-
holder group and to score the outcomes again. Round 3
enabled participants to reﬂect on their scores in light of
the distribution of scores for all stakeholder groups pre-
sented separately and to score the outcomes again.
DelphiManager software was used for online administra-
tion and data management (see Williamson et al., 2017).
Definition of What Constitutes Agreement About a
Common Standard
All outcome domains were retained across all three
rounds of the e-Delphi surveys so that participants
could be free to change their scores across rounds. The
voting threshold was deﬁned, according to recommenda-
tion (Williamson et al., 2012, 2017), as at least 70% of
the participants in all stakeholder groups scoring 7 to 9
and fewer than 15% in any stakeholder group scoring 1
to 3. The reason for this deﬁnition is that consensus
requires agreement by the majority regarding the critical
importance of the outcome domain, with only a small
minority considering it to have little or no importance.
Analysis Methods
Individual survey responses were carefully evaluated in a
series of analyses that used descriptive statistics. We ﬁrst
collated all those outcome domains that reached the pre-
speciﬁed criteria for recommendation as a common stand-
ard for each intervention type and compared across the
three intervention types. We examined the percentage of
participants in each stakeholder group scoring 7 to 9
(in favor) and scoring 1 to 3 (against) in the ﬁnal round
of the e-Delphi surveys and the percentage of respondents
who gave a score of 7 to 9 broken down by stakeholder
group and by round of the e-Delphi survey.
Individual scores in Round 3 were also analyzed stat-
istically to determine the degree of interrater agreement,
within each stakeholder group and in each survey. A
weighted kappa statistic (Fleiss, 1971) was chosen
because this accounts for the meaningful order of the
outcome domain scores and handles study designs with
more than two raters. The 1 to 9 scale was transformed
into the units relevant to the e-Delphi survey (i.e.,
1–3¼ not important, 4–6¼ important but not critical,
7–9 critically important). Following Landis and Koch
(1977), weighted kappa statistics were interpreted as fol-
lows: fair agreement (K¼ 0.21–0.40) and moderate
agreement (K¼ 0.41–0.60).
The similarities and diﬀerences of opinion between
health-care practitioners coming from diﬀerent medical
specialties were explored by examining the average scores
in Round 3, broken down post hoc by specialty subgroups.
Likewise, the similarities and diﬀerences of opinion across
health-care users with diﬀerent durations of chronic tin-
nitus were explored using the same approach.
The ﬁnal analysis considered attrition bias, which
occurs when the participants who do not respond in sub-
sequent rounds have diﬀerent views from their stakeholder
group peers who continue to participate (Williamson et al.,
2017). The potential for attrition bias was investigated
across the three e-Delphi survey rounds according to
methods used by Bruce et al. (2015) in which a graphical
representation is created to compare the response distribu-
tions of withdrawn and completing participants.
Results
The ﬁnal outcome domains identiﬁed by the COMIT’ID
study can be seen in Figure 1. These make up three inter-
vention-speciﬁc core outcome domain sets, recommended
for use in all clinical trials of readily available interventions
for chronic subjective tinnitus in adults. Supplementary
Table S1 provides full details of the percent of participants
who scored each outcome domain as critically important
(i.e., scores 7–9). For the full ﬁndings from all three phases
of the COMiT’ID study, please see the companion article
(Hall et al., 2018). Here, the results focus on addressing the
two issues of interest pertaining to Phase 1, which was the
e-Delphi consensus process.
Importance of Tailoring Outcome Domains to the
Intervention Being Evaluated in the Clinical Trial
Two pieces of evidence support the conclusion that inter-
vention-speciﬁc outcomes are needed when designing
clinical trials in chronic subjective tinnitus.
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Unique outcome domains were considered important to each
intervention type. First, for an outcome domain to be rec-
ommended as a common standard, all four stakeholder
groups needed to reach the 70% threshold rating it as
critically important (scores 7–9), and here, we observed
discriminatory choices according to whether the inter-
vention of interest was sound, psychology, or pharma-
cology based. Table 2 lists all the outcome domains that
reached the prespeciﬁed criteria for recommendation as a
common standard, while Supplementary Table S1 gives
more details on the individual scoring. From the overall
set of 34 recommended outcome domains, 17 of them
(i.e., 50%) were unique to only one intervention
approach. The uniquely relevant outcome domains for
each intervention approach are summarized as follows.
Agreed to be of critical importance only to the sound-
based interventions such as hearing aids and cochlear
implants were eﬀects of tinnitus on hearing (listening,
conversations); perceptions of the tinnitus sound (fre-
quency of occurrence of tinnitus episodes, tinnitus
awareness); and physical health (ability to relax). In con-
trast, agreed to be of critical importance only to pharma-
cological interventions were loudness as a perceptual
characteristic of tinnitus, cognition and thought pro-
cesses (confusion), and potential side eﬀects of drug-
taking (adverse reaction). Finally, agreed to be of critical
importance only for psychological therapies (e.g., talking
or thinking strategies that are aimed at helping people
deal with how tinnitus makes them think and feel)
were cognition and thought processes associated with
tinnitus (tinnitus-related thoughts, negative thoughts/
beliefs, suicidal thoughts, catastrophizing); emotions
associated with tinnitus (worries/concerns, fear, mood,
irritable; and health-related quality of life (impact on
relationships).
In contrast to the 17 outcome domains that were
voted in to just one family of interventions, only 12 out-
come domains (35%) reached the voting threshold for all
three. These were ability to ignore, concentration,
annoyance, anxiety, depressive symptoms, diﬃculties
getting to sleep, quality of sleep, coping, tinnitus intru-
siveness and impacts on individual activities, and social
life and work.
Professional opinion differentiated which domains were deemed
important, according to each intervention type. Second, mem-
bers of the professional stakeholders groups revealed
themselves to be highly discriminatory in their deci-
sion-making according to the intervention type of inter-
est. The COMiT’ID study revealed many examples, but
just three are given here for illustrative purposes. At
Round 3, a much greater percentage of health-care
Figure 1. Graphic illustrating the COMiT’ID recommendations for core outcome domain sets for each family of interventions widely
available for chronic subjective tinnitus in adults.
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practitioners considered ‘‘sense of control’’ to be critic-
ally important for testing the eﬃcacy of sound and
psychology interventions (88% and 96%, respectively)
than for pharmacological interventions (35%). Second,
many more clinical researchers considered ‘‘tinnitus
pitch’’ to be critically important for testing pharmaco-
logical interventions (77%) than for sound- or psychol-
ogy-based interventions (35% and 19%, respectively).
Similar patterns of views were often held across profes-
sional stakeholder groups. For example >75% of the
clinical researchers and commercial representatives and
funders considered pharmacokinetics to be critically
important for trials testing the eﬃcacy of medications,
but <10% considered it to be so when testing the eﬃcacy
of the other interventions. It is worth noting that health-
care practitioners self-selected into each e-Delphi survey
according to their expertise in the particular intervention
strategy, and so this could have contributed to the dis-
criminatory opinions expressed across the three surveys.
For example, as shown in Table 3, otologists were the
predominant health-care specialty in the survey consider-
ing pharmacological interventions, whereas clinical
psychologists put themselves forward with expertise in
psychological interventions alone, and audiologists
Table 2. All Outcome Domains That Reached the Prespecified Consensus Definition Based On the e-Delphi Round 3 Voting.
Sound-based interventions Psychology-based interventions Pharmacology-based interventions
Ability to ignore Ability to ignore Ability to ignore
Ability to relax
Acceptance of tinnitus Acceptance of tinnitus
Adverse reaction
Annoyance Annoyance Annoyance
Anxiety Anxiety Anxiety
Catastrophizing
Concentration Concentration Concentration
Conversations
Confusion
Coping Coping Coping
Depressive symptoms Depressive symptoms Depressive symptoms
Difficulties getting to sleep Difficulties getting to sleep Difficulties getting to sleep
Fear
Frequency of occurrence of tinnitus episodes
Helplessness (lack of control) Helplessness (lack of control)
Impact on individual activities Impact on individual activities Impact on individual activities
Impact on relationships
Impact on social life Impact on social life Impact on social life
Impact on work Impact on work Impact on work
Irritable
Listening
Mood
Negative thoughts/beliefs
Quality of sleep Quality of sleep Quality of sleep
Sense of control Sense of control
Suicidal thoughts
Tinnitus awareness
Tinnitus intrusiveness Tinnitus intrusiveness Tinnitus intrusiveness
Tinnitus loudness
Tinnitus-related thoughts
Tinnitus unpleasantness Tinnitus unpleasantness
Treatment satisfaction Treatment satisfaction
Worries/concerns
Note. Outcome domains presented in bold are unique to only one of the intervention types.
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identiﬁed themselves as experts in sound- and psychol-
ogy-based interventions.
The Recommended Intervention-Specific Outcome
Domains Are Robust
Seven pieces of evidence support the conclusion that the
recommended intervention-speciﬁc outcome domains are
robust.
High agreement across stakeholder groups. First, we
observed that for every recommended outcome
domain, there was a high degree of agreement across
stakeholder groups participating in that e-Delphi
survey. Figure 2 illustrates this point. The solid lines
plotted in the four colors (one for each stakeholder
group) reveal a predominance of Round 3 results pos-
itioned around the outer rim of the three radar plots; a
pattern that indicates that a high percentage of partici-
pants in every group expressed strong views that those
outcome domains were critically important.
High agreement across survey rounds. The radar plots
(Figure 2) also illustrate the second piece of evidence
which is that, for each e-Delphi survey, the scores for
the recommended outcome domains were consistently
high across all three e-Delphi rounds. In Figure 2, the
successive rounds are denoted by dotted, dashed, and
solid lines. For the psychology-based tinnitus interven-
tions, the 70% voting threshold was reached even at
Round 1 for the majority of recommended outcome
domains. In this round, participants were blinded to
the scores given by others. By Round 3, after partici-
pants had the opportunity to reﬂect on the views of
their peers and of others, most of the recommended out-
come domains were being scored at the top of the scale
(8 or 9) with 70% agreement. This same pattern was
broadly repeated for the sound- and pharmacology-
based interventions. Voting tended to be in favor of
inclusion, but the numbers of participants scoring at
the top of the scale for the recommended outcome
domains steadily rose as the survey progressed through
Rounds 1 to 3 and as opinions were shared among
participants.
High agreement within stakeholder groups. Third, we
observed that when all the outcome domains were con-
sidered, weighted kappa statistics indicated acceptable
(fair to moderate) agreement in the Round 3 scores
across the participants in each stakeholder group
(Table 4). Exceptions were for health-care users and clin-
ical researchers in the pharmacology-based survey. It is
not exactly clear why these had poor agreement as
Supplementary Table S1 conﬁrms a high percent scoring
critically important, but we note that clinical researchers
comprised a relatively small group (Table 1) and greater
amounts of data for health-care users were excluded
because scores were in the unable to score category.
Both of these factors might compromise the reliability
of the K statistic.
High agreement across health-care disciplines. The health-
care practitioners who participated in the survey spanned
a diverse range of clinical disciplines (Table 3). The
fourth piece of evidence was that these health-care prac-
titioners were in reasonably good agreement with one
another, even when they had expertise in diﬀerent med-
ical specialties. Figure 3 gives an illustrative example
Table 3. Health-Care Practitioners Who Consented to Participate in the e-Delphi Survey and Then Who Completed Round 3.
Individuals who
consented
Experts in sound-based
interventions
Experts in psychology-based
interventions
Experts in pharmacology-based
interventions
General practitioner 1 0 1 0
Otologist 53 15 13 29
Audiovestibular physician 3 1 1 2
Audiologist 57 30 14 3
Hearing aid technician 2 2 0 0
Hearing therapist 24 6 8 0
Clinical psychologist 14 0 11 0
Psychiatrist 1 1 0 0
Neurologist 1 0 0 1
Psychotherapist 1 0 0 0
Phoniatrician 1 0 0 0
Unknown 6 2 2 2
Total 164 57 50 37
Note. Some experts are represented in more than one e-Delphi survey, especially otologists.
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representing the average scores in Round 3 on the 70
outcome domains for psychology-based interventions.
A high level of agreement in the pattern was found
across the participating otologists, audiologists, hearing
therapists, and clinical psychologists. Where diﬀerences
were observed, it was due to clinical psychologists gen-
erally scoring all outcome domains lower than the other
health-care professionals, not due to any substantive
divergence of opinion on speciﬁc outcome domains.
This supports our conclusion that, despite having diﬀer-
ing expertise and potentially diﬀering vantage points and
priorities for tinnitus, the range of health-care practi-
tioners who participated in the e-Delphi surveys gener-
ally held the same opinion about what outcome domains
should be measured in clinical trials of tinnitus for each
intervention type. A similar pattern in results was
observed for the two other e-Delphi surveys.
High agreement across health-care users, regardless of tinnitus
duration. Fifth, a question asked to health-care users in
the e-Delphi survey enabled us to classify duration of
their chronic tinnitus experience into ﬁve time periods,
Figure 2. Percentage of respondents who gave a score of 7 to 9 for the recommended outcome domains in each family of tinnitus
interventions. Percentages are shown separately for each stakeholder group and for each successive round of the e-Delphi survey. The
percentages at Round 3 determined which outcome domains reached consensus. At this point, the voting threshold was defined as at least
70% of the participants in all stakeholder groups scoring 7 to 9. This 70% cutoff is indicated by the solid black line.
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from 3 months to more than 10 years. A high level of
agreement was observed across health-care users at all
tinnitus durations. For example, the average scores in
Round 3 for the 68 candidate outcome domains for
sound-based interventions showed similar patterns
across all ﬁve durations (Figure 4). As with health-care
practitioners from diﬀerent medical specialties, where
diﬀerences were observed, they were most often a result
of one tinnitus duration group consistently rating all out-
come domains lower rather than any signiﬁcant diver-
gence in scoring individual outcome domains.
Noticeably, those who had experienced tinnitus for
more than 10 years consistently rated all outcome
domains slightly lower for importance, perhaps demon-
strating a greater acceptance or resignation to the
tinnitus and less of a strong reactionary response to the
outcome domains. This supports our conclusion that the
recommended outcome domains are appropriate to all
individuals with chronic subjective tinnitus, regardless
of how long they have experienced it.
Low disagreement across stakeholder groups. Sixth, by deﬁn-
ition, any recommendation for a common standard had
to have fewer than 15% of participants in any stake-
holder group holding the dissenting opinion that the out-
come domain was not important (i.e., scoring 1–3). In
fact, there were very few such opposing voices. Across
those outcome domains listed in Table 2 (reaching 70%
agreement), the median percentage of scores in the not
important category was 0 (range 0%–14%), again
Table 4. Interrater Agreement on the Round 3 Scores Given by Each Stakeholder Group in Each e-Delphi Survey (K¼Weighted Kappa
Statistic; Fleiss, 1971).
e-Delphi survey Stakeholder group K
95% Confidence interval
Lower Upper
Sound-based interventions Health-care users 0.23* 0.17 0.28
Health-care practitioners 0.42** 0.34 0.51
Clinical researchers 0.38* 0.30 0.47
Commercial representatives and funders 0.34* 0.26 0.42
Psychology-based interventions Health-care users 0.24* 0.18 0.31
Health-care practitioners 0.46** 0.38 0.54
Clinical researchers 0.35* 0.28 0.42
Pharmacology-based interventions Health-care users 0.16 0.10 0.22
Health-care practitioners 0.32* 0.26 0.39
Clinical researchers 0.17 0.11 0.22
Commercial representatives and funders 0.53** 0.44 0.62
Note. *Fair agreement (K¼ 0.21–0.40) and **Moderate agreement (K¼ 0.41–0.60).
Figure 3. Average scores given by health-care practitioners in Round 3 of the e-Delphi survey for psychology-based interventions.
Participating specialties were selected for illustrative purposes because of their reasonably balanced size; otologists (n¼ 13), audiologists
(n¼ 14), hearing therapists (n¼ 8), and clinical psychologists (n¼ 11). The pattern for the sound- and pharmacology-based interventions is
similar, but subgroup sizes are uneven.
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indicating the high level of agreement on the importance
of these particular outcome domains for each interven-
tion approach. Supplementary Table S2 gives more
details on the individual scoring. From the comments
submitted in the survey, we can say that when health-
care users scored low, it was often because the outcome
domain was not personally relevant. For example, with
respect to ‘‘quality of sleep,’’ two people said ‘‘I get 7
hours of sleep because of my audio books’’ and ‘‘I get
disturbed sleep for the amount of times I visit the toilet,
not through tinnitus.’’ Professionals tended not to use
the comments box to explain their scores.
Withdrawal or dropout did not appear to affect the final
recommendations. Finally, the retention rate of partici-
pants across the three e-Delphi survey rounds was
good (average¼ 80%), but consensus-based decision-
making can be particularly sensitive to attrition bias
because withdrawal from later rounds can sometimes
be due to holding extreme views not shared by the major-
ity of their stakeholder peers (see Williamson et al.,
2017). Rarely do Core Outcome Set studies look for
and evaluate such potential biases (but see Bruce et al.,
2015). Our attrition analysis results clearly demonstrate
that the average scores for the withdrawn and dropped
out participants who completed only Round 1 (blue bars,
Figure 5) or only Rounds 1 and 2 (blue bars,
Supplementary Figure S1) are well contained within
the average scores of those completing the corresponding
successive rounds (white bars). In other words, on aver-
age, participants who completed the study scored the
outcome domains similarly to those who withdrew or
dropped out from the study, indicating that attrition
bias is unlikely to have aﬀected the outcome domain
recommendations.
Discussion
This article presents an in-depth exploration of the
COMiT’ID study data for the separate e-Delphi surveys
which addressed the three most commonly used types of
tinnitus treatment. The intervention-speciﬁc diﬀerences
in the consensus-based decisions illustrate how the tin-
nitus community recognizes a need to tailor outcome
domains to the speciﬁc intervention being evaluated in
the design of future clinical trials of chronic subjective
tinnitus in adults. The outcome domain recommenda-
tions achieved using this consensus method are robust
across stakeholders, including people with chronic tin-
nitus of all durations and tinnitus professionals working
in all relevant disciplines. Hence, we are conﬁdent that
the views expressed and the subsequent recommenda-
tions are representative of the whole tinnitus community.
One of the strengths of the current study methods is the
value that it has placed in the opinions of people with lived
experience of chronic subjective tinnitus. Involving health-
care users in research and explicitly taking into account
their perspectives is recognized as current best practice to
be conﬁdent that the outcomes measured in a clinical
trial are relevant, appropriate, and of importance in the
real-world clinical setting. Published methods for selecting
outcome instruments recognize that ‘‘patients are regarded
the primary experts regarding patient-reported outcome
measures’’ (Terwee et al., 2018, p. 1165). We designed
Figure 4. Illustrative example of average scores given by health-care users in Round 3 of the e-Delphi survey for sound-based inter-
ventions. Although the number of participants within each time period were not equal, all bands had a reasonable number; 3 months to 1
year (n¼ 12), 2 to 3 years (n¼ 28), 4 to 5 years (n¼ 21), 6 to 10 years (n¼ 27), and more than 10 years (n¼ 58). The pattern for the
psychology- and pharmacology-based interventions is similar, and again subgroup sizes are uneven.
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the consensus process to meet these best practice
requirements, ensuring that the recommended
outcome domains are considered to be important and
critical to all stakeholders alike, including health-care
users alongside clinical researchers and health-care
practitioners.
Another strength concerns the expertise and commit-
ment of the members in the professional stakeholder
groups; the health-care practitioners, clinical researchers,
commercial representatives, and funders. Of particular
note, 67% (i.e., 191/283) of those enrolled participants
were nominated and invited because of their reputation
and research activity. Nevertheless, we do acknowledge
that the degree of knowledge is unknown, and in the case
of the health-care user group, there are likely to be self-
selection biases. The good retention rates across survey
rounds demonstrate the willingness of these profes-
sionals to engage in the process, a factor that is just as
important for participant selection as is degree of know-
ledge (Hsu & Sandford, 2007).
One of the limitations of using a threshold-based cri-
terion is that some outcome domains narrowly missed
inclusion because the votes from just one stakeholder
group failed to reach the threshold by a narrow margin
(within 10%, i.e., 63%–69%). Two outcome domains are
worth highlighting for the impact that this threshold
approach had. Tinnitus unpleasantness and treatment
satisfaction both reached consensus in the sound- and
pharmacology-based surveys but just missed inclusion
in the psychology-based survey because only 64% and
67% of clinical researchers scored 7 to 9, respectively
(Supplementary Table S1). We suggest that if
Figure 5. Round 1 average scores across all outcomes by stakeholder group (health-care users, health-care practitioners, clinical
researchers, and commercial representatives and funders). Blue bars represent those who provided scores in Round 1 only; open bars
represent those scoring in both Rounds 1 and 2.
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investigators wish to add more outcome domains to their
clinical trial designs, then tinnitus unpleasantness and
treatment satisfaction would be worthy of further
consideration.
The diﬀerences between the methodological require-
ments for good clinical trials versus good clinical
research can be somewhat confusing in terms of the spe-
ciﬁcation of appropriate outcomes. Clinical research can
aﬀord to be more exploratory. For example, questions
may seek to shed light on the mechanism of action of the
intervention, ﬁnd an optimal dose, or characterize which
subgroup of patients would be most responsive to a
treatment. In contrast, clinical trials must have a clear
and predeﬁned hypothesized treatment beneﬁt because
they seek to provide a deﬁnitive answer to the question
of whether an intervention for tinnitus is eﬀective
(Higgins et al., 2011). The recommendations arising
from our e-Delphi consensus process are therefore
most applicable to clinical trials, and they can direct
decisions about how to measure expected therapeutic
beneﬁts. In clinical trials, there are three important rea-
sons why it is essential for investigators to clearly deﬁne
outcome domains prior to selecting what questionnaires
or tests to use.
Concept Definition
Many patient-reported questionnaires intend to measure
complex and unobservable concepts, and so it is import-
ant for all investigators to understand the exact nature of
the concept(s) being measured. Indeed, many of the out-
come domains considered in the COMiT’ID study are of
this type. For each outcome domain, the study manage-
ment team engaged health-care users and health-care
practitioners in choosing the wording for the name and
in providing a description of what it meant (Fackrell
et al., 2017; Smith et al., 2018) to ﬂesh out the concept
as a more precisely deﬁned construct. The COMET
handbook v1.0 (Williamson et al., 2017) highlights this
as an important step to avoid ambiguity of language, and
other projects have done likewise (Bruce et al., 2015).
Diﬀerent questionnaires for tinnitus may intend and
claim to be assessing the same concept, but without a
clearly deﬁned common construct as a starting point,
the exact ways in which they each operationalize and
deﬁne the concept with speciﬁc questionnaire items
may result in somewhat diﬀerent constructs which are
not directly equivalent or comparable. This can mean
that across multidomain questionnaires containing sub-
scales that purport to measure the same outcome
domain, the subscale items might actually cover entirely
diﬀerent concepts. Tinnitus intrusiveness is a good exam-
ple. For the COMiT’ID study, our working description
was ‘‘noticing the sound of tinnitus is there and it is
invading your life or your personal space.’’ Important
for our health-care users was that this concept captures
the very negative aspects of the experience, with tinnitus
seen to be an unwanted presence that impedes everyday
functions and activities. Comparing with existing tinni-
tus questionnaires, the intrusiveness subscale of the TQ
seems to go some way toward capturing the same per-
sonal meaning through items such as ‘‘I feel I can never
get away from the noises’’ (p.12) and ‘‘The noises never
‘let up’’’ (p.13) (Hallam, 2009). While the intrusiveness
subscale of the Tinnitus Functional Index asks only
about quantifying the degree of awareness, loudness,
and annoyance of tinnitus on a numerical scale (Meikle
et al., 2012). Interestingly, these three concepts were
identiﬁed as three distinct candidate outcome domains
separate from tinnitus intrusiveness in our COMiT’ID
study, and they did not all reach the voting threshold
to be recommended alongside tinnitus intrusiveness.
The concept descriptions generated during the
COMiT’ID study provide an invaluable resource so
that ambiguity of language is minimized, and all investi-
gators precisely understand the concepts that have been
recommended. Because the descriptions were always vis-
ible to participants in the e-Delphi survey, we can be
conﬁdent that the scoring was conducted on this basis.
Content Validity
This is the most important measurement property of any
patient-reported questionnaire so that investigators can
be conﬁdent in selecting the most valid instrument for
quantifying the expected treatment-related change
(Prinsen et al., 2018; Terwee et al., 2018). Content valid-
ity is emphasized by regulatory authorities, such as the
U.S. Food and Drug Administration (U.S. Department
of Health and Human Services Food and Drug
Administration, Center for Drug Evaluation and
Research, Center for Biologics Evaluation and
Research, & Center for Devices and Radiological
Health, 2009) and the European Medicines Agency
(Committee for Medicinal Products for Human Use,
2005). To have content validity, a questionnaire should
contain items that are all relevant to the concept within a
speciﬁc population and context of use, it should be com-
prehensive with respect to patient concerns with no
important aspects missing, and it should be understood
by patients as intended.
The work presented here is important with respect to
content validity because it deﬁnes the scope of the con-
cepts that are considered to be critically important when
assessing whether or not an intervention of interest has
worked. For example, eﬀects of tinnitus on the ability to
understand somebody talking (e.g., TV and radio) and
on the ability to listen, understand, and take part in con-
versations were agreed to be of critical importance only
to the sound-based interventions. Conversely, questions
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about ‘‘listening’’ and ‘‘conversations’’ are not necessary
to ask when assessing psychology- and pharmacology-
based interventions.
Responsiveness
Greater knowledge about the sensitivity of any instrument
with respect to its ability to measure treatment-related
change is important so that investigators can be conﬁdent
in selecting the best performing measurement for use as an
end point in a clinical trial. Such knowledge can also help
to understand what size of change to expect so that the
clinical trial can be adequately powered to detect that
beneﬁt (Jones, Carley, & Harrison, 2003). Our recommen-
dations for tailored outcome domains are relevant to both
of these considerations. It is reasonable to assume that
those outcome domains that have been carefully chosen
by tinnitus experts for their suitability as outcomes in a
clinical trial could point to speciﬁc scales or instruments
that have a high likelihood of being responsive. Numerous
multidomain tinnitus questionnaires already exist that
contain items corresponding to some of the outcome
domains identiﬁed by the consensus process. However,
while multidomain questionnaires may meet clinical
needs, such as for selecting or categorizing patients, they
are less useful as tools for assessing outcome in clinical
trials. Unless all the items and subscales in an instrument
are relevant to the intervention being tested, then infor-
mation can be lost (Hallam, 2009) or diﬃcult to interpret
(Johnston et al., 2013) when a composite global score is
employed as a measure of change over time. An alterna-
tive approach is to select a number of measurement instru-
ments, each one corresponding to one outcome domain,
and this is the approach that we advocate. For example,
we have explored trial data to show that a patient-
reported measure of tinnitus loudness using a Likert
scale is probably able to detect only large changes (at
least 3.5 points out of 11; Hall, Mehta, & Fackrell, 2017).
Terwee et al. (2018) have cautioned that content validity
does not necessarily mean that the instrument is respon-
sive. For example, one might measure the incomplete or
incorrect concept very reliably, and a real change in the
concept of interest may be over or underestimated due to
irrelevant or missing items. Our previous examination of
tinnitus loudness measures indicates that an investigator-
administered test of loudness matching failed to measure a
sensation that was meaningful to people who lived with
the experience of tinnitus and hence probably has poor
content validity (Hall et al., 2017).
The current work focuses on the selection of outcomes
to provide conﬁrmatory evidence of clinical eﬃcacy.
Nevertheless, there can be much to gain in a clinical
trial by collecting qualitative data that are not constrained
by a priori determination. For example, the UK Medical
Research Council framework recommends that both
qualitative and quantitative methods are important
when evaluating complex interventions, that is, those
that contain several interacting therapeutic components
(Craig et al., 2008). Qualitative data could help to access
the thoughts and feelings of participants, enabling a richer
understanding of the meaning that people ascribe to their
experiences of the tinnitus intervention. In particular, we
would advocate qualitative data to explore the way in
which an intervention is implemented, to shed light on
why an intervention might have failed or had unexpected
consequences or to understand why a successful interven-
tion worked and how it could be further optimized.
Conclusions and Next Steps
Developing and employing a common standard for clin-
ical trials of chronic subjective tinnitus would aid the
global tinnitus community in developing a shared under-
standing of the concepts underpinning each tinnitus-
related domain, in creating a convention for labeling
those domain concepts, and in recommending which
domains are most relevant to be measured as clinical
trial outcomes that might provide conﬁrmatory evidence
for clinical eﬃcacy. The COMiT’ID study and resulting
core outcome domain set recommendations are intended
to provide this framework for greater comparability
across clinical trials. The next step is gaining wider aware-
ness and endorsement of the core outcome domains
across the global tinnitus community; hence, the import-
ance of reporting the e-Delphi process and fully explain-
ing the ﬁndings to ensure misunderstanding does not
inadvertently become a barrier to implementation and
uptake. From this article, it should be clear that the out-
come domain recommendations are robust, supported by
and representative of the wide variety of tinnitus stake-
holders, and also that the split between sound-, psych-
ology-, and pharmacology-based interventions is justiﬁed.
It is premature to recommend any existing instrument
as the preferred instrument as this will require rigorous
evaluation of content validity for the recommended out-
come domains and health-care users’ interpretation and
against the standards required by the regulatory autho-
rities, commissioners of health-care services, and health
insurers. However, the COMiT’ID study takes us one
step closer. We strongly urge investigators seeking to
use the best available evidence base to select outcomes
in a tinnitus clinical trial to consider the COMiT
recommendations.
Acknowledgments
We thank Professor Paula Williamson, University of Liverpool,
for commenting on the study protocol; Richard Crew,
University of Liverpool, for providing access to the
DelphiManager software and for managing the data; and Felix
Meyer for analyzing the data for attrition bias. The COMiT’ID
14 Trends in Hearing
team acknowledges the support of the National Institute for
Health Research (NIHR) Clinical Research Network in partici-
pant recruitment, and our public research partners—Brian
Thacker and Veronica Colley—for their input into study design.
Declaration of Conflicting Interests
The authors declared no potential conﬂicts of interest with respect
to the research, authorship, and/or publication of this article.
Funding
The authors disclosed receipt of the following ﬁnancial support
for the research, authorship, and/or publication of this article:
This work was primarily funded through the NIHR Nottingham
Biomedical Research Centre and European Cooperation in
Science and Technology Action (BM1306). D. A. H. is an
NIHR senior investigator. Small research grants were awarded
by Action on Hearing Loss to purchase relevant software licenses
and to create the Introduction video described in this article and
by British Tinnitus Association to support Public Research
Partner Involvement. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation
of the article. The views expressed in this article are those of the
authors and not necessarily those of the National Health Service,
the NIHR, or the Department of Health and Social Care.
ORCID iD
Deborah A. Hall http://orcid.org/0000-0002-3804-1452
Supplemental Material
Supplemental material for this article is available online.
References
Baguley, D., McFerran, D., & Hall, D. (2013). Tinnitus. The
Lancet, 382(9904), 1600–1607. doi:10.1016/S0140-6736(13)
60142-7
Bruce, I., Harman, N., Williamson, P., Tierney, S., Callery, P.,
Mohiuddin, S., . . .O’Brien, K. (2015). The management of
Otitis Media with Effusion in children with cleft palate
(mOMent): A feasibility study and economic evaluation.
Health Technology Assessment, 19(68), 1. doi: 10.3310/
hta19680.
Committee for Medicinal Products for Human Use. (2005).
Reflection paper on the regulatory guidance for the use of
health-related quality of life (HRQL) measures in the evalu-
ation of medicinal products (Doc. Ref. EMEA/CHMP/EWP/
139391/2004). London, England: European Medicines
Agency.
Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I., &
Petticrew, M. (2008). Developing and evaluating complex
interventions: The new Medical Research Council guidance.
BMJ, 337(2008), a1655. doi: 10.1136/bmj.a1655.
Fackrell, K., Smith, H., Colley, V., Thacker, B., Horobin, A.,
Haider, H. F., . . .Hall, D. A. (2017). Core Outcome
Domains for early phase clinical trials of sound-, psych-
ology-, and pharmacology-based interventions to manage
chronic subjective tinnitus in adults: The COMIT’ID
study protocol for using a Delphi process and face-to-face
meetings to establish consensus. Trials, 18(1), 388.
doi:10.1186/s13063-017-2123-0
Fleiss, J. L. (1971). Measuring nominal scale agreement among
many raters. Psychological Bulletin, 76(5), 378. doi:10.1037/
h0031619
Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek,
J., Vist, G., . . . Schu¨nemann, H. J. (2011). GRADE guide-
lines: 2. Framing the question and deciding on important
outcomes. Journal of Clinical Epidemiology, 64(4), 395–400.
doi:10.1016/j.jclinepi.2010.09.012
Hall, D. A., Fackrell, K., Li, A. B., Thavayogan, R., Smith, S.,
Kennedy, V., . . .Haider, H. F. (2018). A narrative synthesis
of research evidence for tinnitus-related complaints as
reported by patients and their significant others. Health
and Quality of Life Outcomes, 16(1), 61. doi:10.1186/
s12955-018-0888-9
Hall, D. A., Haider, H., Szczepek, A. J., Lau, P., Rabau, S.,
Jones-Diette, J., . . .Fuller, T. (2016). Systematic review of
outcome domains and instruments used in clinical trials of
tinnitus treatments in adults. Trials, 17(1), 270. doi:10.1186/
s13063-016-1399-9
Hall, D. A., La´inez, M. J., Newman, C. W., Sanchez, T. G.,
Egler, M., Tennigkeit, F., . . .Langguth, B. (2011).
Treatment options for subjective tinnitus: Self reports
from a sample of general practitioners and ENT physicians
within Europe and the USA. BMC Health Services
Research, 11(1), 302. doi:10.1186/1472-6963-11-302
Hall, D. A., Mehta, R. L., & Fackrell, K. (2017). How to
choose between measures of tinnitus loudness for clin-
ical research? A report on the reliability and validity of an
investigator-administered test and a patient-reported meas-
ure using baseline data collected in a phase IIa drug trial.
American Journal of Audiology, 26(3), 338–346. doi:10.1044/
2017_AJA-16-0129
Hall, D. A., Smith, H., Hibbert, A., Colley, V., Haider, H. F.,
Horobin, A., . . . Fackrell, K. (2018). The COMiT’ID study:
Developing core outcome domains sets for clinical trials of
sound-, psychology-, and pharmacology-based interven-
tions for chronic subjective tinnitus in adults. Trends in
Hearing 22: 2331216518814384. doi: 10.1177/
2331216518814384
Hallam, R. S. (2009). TQ manual of the tinnitus questionnaire,
revised and updated. London, England: Polpresa Press.
Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Ju¨ni, P., Moher,
D., Oxman, A. D., . . . Sterne, J. A. (2011). The Cochrane
Collaboration’s tool for assessing risk of bias in randomised
trials. BMJ, 343, d5928. doi:10.1136/bmj.d5928
Hsu, C. C., & Sandford, B. A. (2007). The Delphi technique:
Making sense of consensus. Practical Assessment, Research
& Evaluation, 12(10), 1–8. Retrieved from http://pareonline.
net/getvn.asp?v¼12&n¼10
Johnston, B. C., Patrick, D. L., Busse, J. W., Schu¨nemann, H.
J., Agarwal, A., Guyatt, G. H. (2013). Patient-reported out-
comes in meta-analyses – Part 1: Assessing risk of bias and
combining outcomes. Health and Quality of Life Outcomes,
11(1), 109. doi:10.1186/1477-7525-11-109
Jones, S. R., Carley, S., & Harrison, M. (2003). An introduc-
tion to power and sample size estimation. Emergency
Medicine Journal, 20(5), 453–458. doi:10.1136/emj.20.5.453
Hall et al. 15
Kennedy, V., Wilson, C., & Stephens, D. (2004). Quality of
life and tinnitus. Audiological Medicine, 2(1), 29–40.
doi:10.1080/16513860410027349
Kuk, F. K., Tyler, R. S., Russell, D., & Jordan, H. (1990). The
psychometric properties of a tinnitus handicap question-
naire. Ear and Hearing, 11(6), 434–445.
Landgrebe, M., Azevedo, A., Baguley, D., Bauer, C., Cacace,
A., Coelho, C., . . . van de Heyning, P. (2012).
Methodological aspects of clinical trials in tinnitus: A pro-
posal for an international standard. Journal of
Psychosomatic Research, 73(2), 112–121. doi:10.1016/j.
jpsychores.2012.05.002
Landis, J. R., & Koch, G. G. (1977). The measurement of
observer agreement for categorical data. Biometrics, 33,
159–174. doi:10.2307/2529310
Londero, A., & Hall, D. A. (2017). Call for an evidence-based
consensus on outcome reporting in tinnitus intervention stu-
dies. Frontiers in Medicine, 4, 42. doi:10.3389/
fmed.2017.00042
Martinez-Devesa, P., Perera, R., Theodoulou, M., & Waddell,
A. (2010). Cognitive behavioural therapy for tinnitus.
Cochrane Database of Systematic Reviews, (9). CD005233.
doi:10.1002/14651858.CD005233.pub3
Meikle, M. B., Henry, J. A., Griest, S. E., Stewart, B. J.,
Abrams, H. B., McArdle, R., . . .Folmer, R. L. (2012). The
tinnitus functional index: Development of a new clinical
measure for chronic, intrusive tinnitus. Ear and Hearing,
33(2), 153–176. doi:10.1097/AUD.0b013e31822f67c0
Newman, C. W., Jacobson, G. P., & Spitzer, J. B. (1996).
Development of the tinnitus handicap inventory. Archives
of Otolaryngology – Head & Neck Surgery, 122(2), 143–148.
doi:10.1001/archotol.1996.01890140029007.
Prinsen, C. A. C., Mokkink, L. B., Bouter, L. M., Alonso, J.,
Patrick, D. L., de Vet, H. C. W., & Terwee, C. B. (2018).
COSMIN guideline for systematic reviews of patientre-
ported outcome measures. Quality of Life Research, 27(5),
1147–1157. doi:10.1007/s11136-018-1798-3
Smith, H., Horobin, A., Fackrell, K., Colley, V., Thacker, B.,
& Hall, D. A. (2018). Defining and evaluating novel
procedures for involving patients in core outcome set
research: Creating a meaningful long list of candidate out-
come domains. Research Involvement and Engagement, 4(1),
8. doi:10.1186/s40900-018-0091-5
Terwee, C. B., Prinsen, C. A. C., Chiarotto, A., Westerman, M.
J., Patrick, D. L., Alonso, J., . . .Mokkink, L. B. (2018).
COSMIN methodology for evaluating the content validity
of patient-reported outcome measures: A Delphi study.
Quality of Life Research, 27(5), 1159–1170. doi:10.1007/
s11136-018-1829-0
Tunkel, D. E., Bauer, C. A., Sun, G. H., Rosenfeld, R. M.,
Chandrasekhar, S. S., Cunningham, E. R. Jr., . . .Henry, J.
A. (2014). Clinical practice guideline: Tinnitus.
Otolaryngology – Head and Neck Surgery, 151(2 Suppl),
S1–S40. doi:10.1177/0194599814545325
Tyler, R. S., Oleson, J., Noble, W., Coelho, C., & Ji, H. (2007).
Clinical trials for tinnitus: Study populations, designs,
measurement variables, and data analysis. Progress in Brain
Research, 166, 499–509. doi:10.1016/S0079-6123(07)66048-8
U.S. Department of Health and Human Services Food and
Drug Administration. (1998). Guidance for industry on pro-
viding clinical evidence of effectiveness for human drugs and
biological products. Rockville, MD: Food and Drug
Administration.
U.S. Department of Health, Human Services Food and Drug
Administration, Center for Drug Evaluation and Research,
Center for Biologics Evaluation and Research, & Center for
Devices and Radiological Health. (2009). Guidance for
industry patient-reported outcome measures: Use in medical
product development to support labeling claims. Rockville,
MD: Food and Drug Administration.
Williamson, P. R., Altman, D. G., Bagley, H., Barnes, K. L.,
Blazeby, J. M., Brookes, S. T., . . .Kirkham, J. J. (2017). The
COMET handbook: Version 1.0. Trials, 18(3), 280.
doi:10.1186/s13063-017-1978-4
Williamson, P. R., Altman, D. G., Blazeby, J. M., Clarke, M.,
Devane, D., Gargon, E., & Tugwell, P. (2012). Developing
core outcome sets for clinical trials: Issues to consider.
Trials, 13(1), 132. doi:10.1186/1745-6215-13-132
16 Trends in Hearing
